Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis

US9879061B2 · kind B2 · utility

Assignees

• The Board of Trustees of the Leland Stanford Junior University · US
• ARAVIVE BIOLOGICS, INC. · US

Inventors

• Patrick O'Connor · Attleboro, US
• Raymond Tabibiazar · Portola Valley, US
• Amato J. Giaccia · Stanford, US
• Erinn Bruno Rankin · Waltham, US
• Jennifer R. Cochran · Stanford, US
• Douglas Jones · Newton, US
• Mihalis Kariolis · South San Francisco, US
• Katherine Fuh · Chesterfield, US
• Yu Miao · Sunnyvale, US

Key dates

• Filing date: Dec 14, 2012
• Grant date: Jan 30, 2018
• Expiry date: Oct 6, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compositions and methods are provided for alleviating endometriosis, kidney disease, inflammatory disease and/or transplant rejection in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.